Biodexa Pharmaceuticals (BDRX) Non Operating Interest Expenses (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Non Operating Interest Expenses across 13 years of filings, most recently posting -$180096.2 for Q2 2025.

• In Q2 2025, Non Operating Interest Expenses changed N/A year-over-year to -$180096.2; the TTM figure through Jun 2025 stood at -$321405.0 (changed N/A YoY), while the FY2025 annual figure was -$301938.9, down 43.16% from the prior year.
• Non Operating Interest Expenses came in at -$180096.2 for Q2 2025 at Biodexa Pharmaceuticals, down from -$62891.6 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of -$27530.0 in Q2 2023 to a low of -$216759.6 in Q3 2021.
• Average Non Operating Interest Expenses over 5 years is -$105037.6, with a median of -$62528.4 recorded in 2022.
• Year-over-year, Non Operating Interest Expenses sank 682.41% in 2021 and surged 86.31% in 2022.
• Over 5 years, Non Operating Interest Expenses stood at -$210289.7 in 2021, then surged by 70.44% to -$62165.2 in 2022, then rose by 18.14% to -$50887.2 in 2023, then fell by 23.59% to -$62891.6 in 2024, then sank by 186.36% to -$180096.2 in 2025.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$180096.2 in Q2 2025, -$62891.6 in Q4 2024, and -$50887.2 in Q4 2023.